Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

ennl
Careers MediaContact us
ennl
Careers MediaContact us

Investors

Share Price

SEQUANA MEDICAL

ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33

EURO 22.40

XXXXX.XX

+2.18%
SEE THE PRICE CHART

For more information, please consult Euronext

Prev close
21.84
Open
20.60
Volume
17578
Lowest price
10.10
Highest price
20.20
Bid price
20.60
Ask price
20.60
Trading sessions
200
Capitalization
246.01M

Share Data

Status as of 25 March 2024

  • Outstanding share capital: EUR 3,720,562.60
  • Outstanding voting securities: 35,909,420 shares
  • Outstanding voting rights (“denominator”): 35,909,420 voting rights
  • Voting securities that can still be issued: 4,792,765 shares (each share entailing one voting right)
Major Shareholdings

Last update: 11 april 2024

Overview of major shareholdings

This graph represents Sequana Medical’s major shareholders, based on transparency notifications received by the Company, to date.

Overview of transparency notifications received to date

The Belgian Transparency Act refers to article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provision.
Pursuant to this Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

For more information and the appropriate transparency forms, please contact Sequana Medical Investor Relations (ir@sequanamedical.com) or the FSMA.

Shareholder Date of notification Transparency notification Press release
Adrianus van Herk 08-Apr-2024 Download pdf 11-Apr-2024
EQT Life Sciences Group B.V. 10-Apr-2024 Download pdf 11-Apr-2024
EQT Life Sciences Group B.V. 04-Apr-2024 Download pdf 11-Apr-2024
LSP Management Group B.V. 08-Apr-2024 Download pdf 11-Apr-2024
Optiverder B.V. 03-Apr-2024 Download pdf 08-Apr-2024
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA 02-Apr-2024 Download pdf 08-Apr-2024
GRAC société simple 28-Mar-2024 Download pdf 08-Apr-2024
ParticipatieMaatschappij Vlaanderen NV 03-Apr-2024 Download pdf 03-Apr-2024
Adrianus van Herk 28-Mar-2024 Download pdf 03-Apr-2024
MCMI 19-Jan-2024 Download pdf 24-Jan-2024
Erik Amble / NeoMed Management / NeoMed IV 16-Jan-2024 Download pdf 24-Jan-2024
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA 11-Jan-2024 Download pdf 15-Jan-2024
Optiverder BV 10-May-2023 Download pdf 15-May-2023
Participatiemaatschappij Vlaanderen NV 11-May-2023 Download pdf 15-May-2023
NeoMed IV Extension Limited / NeoMed Innovation V Limited 06-Feb-2023 Download pdf 09-Feb-2023
Rosetta Capital Ltd 06-Feb-2023 Download pdf 09-Feb-2023
GRAC société simple 22-Mar-2022 Download pdf 28-Mar-2022
Partners in Equity V B.V. 16-Mar-2022 Download pdf 18-Mar-2022
Newton Biocapital I SA 15-Mar-2022 Download pdf 18-Mar-2022
Sensinnovat BV 15-Mar-2022 Download pdf 18-Mar-2022
NeoMed IV Extension Limited / NeoMed Innovation V Limited 14-Mar-2022 Download pdf 18-Mar-2022
Venture Incubator AG / VI Partners AG 19-Feb-2021 Download pdf 23-Feb-2021
LSP Health Economics Fund Management B.V. 19-Feb-2021 Download pdf 23-Feb-2021
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 19-Feb-2021 Download pdf 23-Feb-2021
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA 18-Feb-2020 Download pdf 21-Feb-2020
Capricorn Heath-tech Fund NV / Quest for Growth NV 14-Feb-2020 Download pdf 21-Feb-2020
GRAC Société Simple 30-Jan-2020 Download pdf 03-Feb-2020
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 30-Jan-2020 Download pdf 03-Feb-2020
Newton Biocapital I Pricav Privée SA 21-Feb-2019 Download pdf 25-Feb-2019
Venture Incubator AG / VI Partners AG 21-Feb-2019 Download pdf 25-Feb-2019
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 20-Feb-2019 Download pdf 25-Feb-2019
LSP Health Economics Fund Management B.V. 19-Feb-2019 Download pdf 25-Feb-2019
Federale Participatie- en Investeringsmaatschappij N.V. 18-Feb-2019 Download pdf 25-Feb-2019
Participatiemaatschappij Vlaanderen NV 18-Feb-2019 Download pdf 25-Feb-2019
Capricorn Health-tech Fund NV / Quest for Growth NV 18-Feb-2019 Download pdf 25-Feb-2019
Shareholder Meetings

May 23, 2024

Annual and Extraordinary General Meetings

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2023

XBRL Annual report 2023 – European Single Electronic Format (ESEF) – Dutch only

Statutory annual accounts for the year ended 31 December 2023

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2023

Statutory auditor’s report on the annual accounts for the year ended 31 December 2023

Report of the Board of Directors on the annual accounts for the year ended 31 December 2023

Report of the Board of Directors in accordance with Articles 7:179 and 7:197 of the Belgian Companies and Associations Code (with the report of the statutory auditor in accordance with Article 7:197 of the Belgian Companies and Associations Code)

Special Report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code

Report of the statutory auditor in accordance with Article 7:179 of the Belgian Companies and Associations Code (Dutch language version only)

Draft Remuneration Policy

Advice of the ad hoc committee of independent directors in accordance with Article 7:179 of the Belgian Companies and Associations Code

November 10, 2023

Extraordinary General Meeting

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Special report of the Board of Directors

Report of the Board of Directors

June 26, 2023

Special General Meeting

Minutes SGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

May 25, 2023

Annual General Meeting

Minutes AGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2022

Annual report 2022 – European Single Electronic Format (ESEF) – Dutch only

Statutory annual accounts for the year ended 31 December 2022

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2022

Statutory auditor’s report on the annual accounts for the year ended 31 December 2022

Report of the Board of Directors on the annual accounts for the year ended 31 December 2022

Report of the board of directors in accordance with article 7:228 of the Belgian Companies and Associations Code

February 10, 2023

Extraordinary General Meeting

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Report of the Board of Directors

Report of the Statutory Auditor

Remuneration Policy

May 27, 2022

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2021

Annual report 2021 – European Single Electronic Format (ESEF) – Dutch only

Statutory annual accounts for the year ended 31 December 2021

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2021

Statutory auditor’s report on the annual accounts for the year ended 31 December 2021

Statutory auditor’s report on the Bootstrap Warrants

Report of the Board of Directors on the annual accounts for the year ended 31 December 2021

Report of the Board of Directors on the renewal of the authorised capital

Report of the Board of Directors on the Bootstrap Warrants

Remuneration Policy

May 27, 2021

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2020

Statutory annual accounts for the year ended 31 December 2020

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2020

Statutory auditor’s report on the annual accounts for the year ended 31 December 2020

Statutory auditor’s report on the 2021 Share Options (full version in Dutch only)

Report of the Board of Directors on the annual accounts for the year ended 31 December 2020

Report of the Board of Directors on the renewal of the authorised capital

Report of the Board of Directors on the 2021 Share Options

May 28, 2020

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Explanatory Note

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights

Annual report 2019

Statutory annual accounts for the year ended 31 December 2019

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2019

Statutory auditor’s report on the annual accounts for the year ended 31 December 2019

May 23, 2019

Annual General Meeting

Minutes

Invitation

Explanatory Note

Proxy Form NL/EN

Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)

Outstanding Shares and Voting Rights

Attendance Form EN / Attendance Form NL (please complete the Dutch form)

Annual report 2018

Statutory annual accounts for the year ended 31 December 2018

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2018

Statutory auditor’s report on the annual accounts for the year ended 31 December 2018

April 25, 2019

Extraordinary General Meeting

Minutes NL

Invitation

Explanatory Note

Proxy Form EN / Proxy Form NL (please complete the Dutch form)

Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)

Outstanding Shares and Voting Rights

Attendance Form EN / Attendance Form NL (please complete the Dutch form)

Other Regulated Information

March 25, 2024

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor (Dutch only)

November 6, 2023

Article 7:198 juncto articles 7:180 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors (Dutch only)

Report of the Statutory Auditor (Dutch only)

October 4, 2023

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors (Dutch only)

Report of the Statutory Auditor (Dutch only)

April 24, 2023

Article 7:198 juncto articles 7:179, 7:180 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor

March 07, 2022

Article 7:198 juncto articles 7:179, 7:191 and 7:193 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor

March 25, 2021

Article 7:198 juncto articles 7:179 and 7:197 of the Belgian companies and Associations Code

Report of the Board of Directors – Dutch only

Report of the Statutory Auditor – Dutch only

February 9, 2021

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor – full version in Dutch only

January 27, 2020

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor on the proposal of a capital increase (within the framework of the authorized capital) with cancellation of the preferential subscription right – full version in Dutch only

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES